Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026
Rhea-AI Summary
Teva (NYSE:TEVA) will release its fourth quarter 2025 financial results on Wednesday, January 28, 2026 at 7:00 a.m. ET.
Teva will host a conference call and live webcast the same day at 8:00 a.m. ET. Investors must register in advance to obtain local or toll-free dial-in numbers and a personal PIN. A live webcast will be available at https://ir.tevapharm.com/Events-and-Presentations, and a replay will be posted within 24 hours on the same site.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves: UTHR +0.61%, TAK +0.35%, RDY -0.5%, NBIX -1.43%, VTRS flat, suggesting company-specific positioning rather than a broad sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 09 | NDA submission | Positive | +0.8% | FDA NDA filing for olanzapine LAI supported by positive Phase 3 data. |
| Nov 25 | EU approvals | Positive | +0.9% | EU marketing authorizations for two denosumab biosimilars supporting biosimilar strategy. |
| Nov 21 | Investor conferences | Neutral | +2.3% | Multiple December healthcare conference presentations announced for senior management. |
| Nov 19 | AI initiative | Positive | -1.6% | Launch of Teva Rise open innovation platform targeting AI and smart manufacturing. |
| Nov 07 | Clinical data | Positive | +1.2% | Interim real-world AUSTEDO data showing improved TD symptoms and AIMS score. |
Recent fundamental and clinical news often coincided with modest positive moves, while strategic/AI initiatives saw some negative reaction.
Over the last six weeks, Teva reported several positive developments, including an FDA NDA submission for olanzapine LAI on Dec 9, 2025 and European Commission approvals for two denosumab biosimilars on Nov 25, 2025, both followed by modest gains. Investor conferences in early December 2025 and positive real‑world AUSTEDO data in Nov 2025 also aligned with upward moves, while the AI-focused Teva Rise launch on Nov 19, 2025 saw a negative reaction.
Market Pulse Summary
This announcement sets the timetable for Teva’s Q4 2025 financial results release at 7:00 a.m. ET on January 28, 2026, followed by an 8:00 a.m. ET conference call and webcast. Historically, similar quarterly scheduling notices averaged a 1.47% move, indicating modest positioning rather than major repricing. Investors may focus on how upcoming results relate to recent NDA, biosimilar approvals, and clinical updates already disclosed.
AI-generated analysis. Not financial advice.
TEL AVIV, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter 2025 financial results on Wednesday, January 28, 2026, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.
In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin.
A live webcast of the call will be available on Teva's website at: https://ir.tevapharm.com/Events-and-Presentations.
Following the conclusion of the call, a replay of the webcast will be available within 24 hours on Teva's website.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This Document and the presentation at the conferences may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, to sustain and focus our portfolio of generic medicines, and to execute on our organizational transformation and to achieve expected cost savings; our significant indebtedness; our business and operations in general; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in our Quarterly Report on Form 10-Q for the third quarter of 2025 and in our Annual Report on Form 10-K for the year ended December 31, 2024, including in the section captioned “Risk Factors” and “Forward Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
Teva Media Inquiries
TevaCommunicationsNorthAmerica@tevapharm.com
Teva Investor Relations Inquiries
TevaIR@Tevapharm.com
FAQ
When will Teva (TEVA) announce Q4 2025 results and when is the conference call?
How can investors join the Teva (TEVA) January 28, 2026 conference call?
Where will the Teva (TEVA) live webcast of the Jan 28, 2026 call be available?
Will there be a replay of Teva's (TEVA) Jan 28, 2026 webcast and when will it be available?
What time zone are the Teva (TEVA) announcement and call times listed in for Jan 28, 2026?
Is prior registration required to access Teva's (TEVA) Jan 28, 2026 call replay?
